Investors
Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.


Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.

Investors

3:58 PM EDT • Aug 4, 2021
QTNT
3.585USD
4.52%
Contact

Peter Buhler, Chief Financial Officer 

IR@quotientbd.com

3 Months
6 Months
12 Months
Quotient Ltd
USD

Events & presentations

Quotient Limited to Report First Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient Limited to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Press releases

Quotient Limited Announces Equity Awards
Quotient Limited to Report First Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient Limited Announces Departure of Chief Financial Officer, Peter Buhler
Financials & filings

Get up-to-date information about our Company’s financials.

Corporate governance

Retrieve corporate policy documents, committee charters, and more. 

Stock information

Follow our latest stock quote and historical information.

Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.